Yousif Capital Management LLC Buys 234 Shares of Penumbra, Inc. (NYSE:PEN)

Yousif Capital Management LLC grew its stake in Penumbra, Inc. (NYSE:PEN) by 1.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,399 shares of the company’s stock after purchasing an additional 234 shares during the quarter. Yousif Capital Management LLC’s holdings in Penumbra were worth $4,628,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of PEN. SG Americas Securities LLC raised its position in shares of Penumbra by 102.7% in the third quarter. SG Americas Securities LLC now owns 4,053 shares of the company’s stock valued at $980,000 after purchasing an additional 2,053 shares during the period. Linden Thomas Advisory Services LLC raised its position in shares of Penumbra by 16.1% in the third quarter. Linden Thomas Advisory Services LLC now owns 5,651 shares of the company’s stock valued at $1,367,000 after purchasing an additional 784 shares during the period. Xponance Inc. grew its stake in shares of Penumbra by 1.1% in the third quarter. Xponance Inc. now owns 8,482 shares of the company’s stock valued at $2,052,000 after acquiring an additional 92 shares in the last quarter. New York State Teachers Retirement System grew its stake in shares of Penumbra by 4.6% in the third quarter. New York State Teachers Retirement System now owns 37,688 shares of the company’s stock valued at $9,117,000 after acquiring an additional 1,652 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Penumbra by 18.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,055 shares of the company’s stock valued at $1,707,000 after acquiring an additional 1,079 shares in the last quarter. 88.88% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. TheStreet upgraded shares of Penumbra from a “d+” rating to a “c-” rating in a research note on Friday, January 12th. Royal Bank of Canada restated an “outperform” rating and issued a $289.00 price target on shares of Penumbra in a research note on Friday, February 23rd. Piper Sandler restated an “overweight” rating and issued a $290.00 price target on shares of Penumbra in a research note on Wednesday, April 3rd. JPMorgan Chase & Co. downgraded shares of Penumbra from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $284.00 to $250.00 in a research note on Friday, February 23rd. Finally, Truist Financial decreased their price target on shares of Penumbra from $290.00 to $280.00 and set a “buy” rating on the stock in a research note on Friday, March 22nd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $304.45.

Insider Activity

In other news, EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $237.68, for a total value of $142,608.00. Following the sale, the executive vice president now directly owns 62,997 shares in the company, valued at approximately $14,973,126.96. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $237.68, for a total value of $142,608.00. Following the sale, the executive vice president now directly owns 62,997 shares in the company, valued at approximately $14,973,126.96. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Arani Bose sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $250.20, for a total transaction of $1,876,500.00. Following the completion of the sale, the director now owns 164,294 shares in the company, valued at $41,106,358.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,648 shares of company stock worth $2,369,903. Corporate insiders own 5.30% of the company’s stock.

Penumbra Trading Down 0.5 %

Shares of Penumbra stock opened at $204.41 on Friday. The company has a market capitalization of $7.92 billion, a price-to-earnings ratio of 88.49, a PEG ratio of 2.03 and a beta of 0.51. The company has a quick ratio of 3.49, a current ratio of 6.06 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 12-month low of $180.93 and a 12-month high of $348.67. The firm’s 50-day moving average price is $228.07 and its two-hundred day moving average price is $231.75.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.05. Penumbra had a net margin of 8.59% and a return on equity of 7.49%. The firm had revenue of $284.68 million for the quarter, compared to the consensus estimate of $286.62 million. During the same period in the prior year, the company posted $0.16 earnings per share. The business’s revenue for the quarter was up 28.7% on a year-over-year basis. On average, analysts forecast that Penumbra, Inc. will post 2.85 earnings per share for the current fiscal year.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.